Morgan Stanley lowered the firm’s price target on Cabaletta Bio (CABA) to $22 from $30 and keeps an Overweight rating on the shares. The RESET clinical program for rese-cel continues and while a safety update was provided that could raise concerns, the firm notes that the update was related to a protocol deviation and no changes were recommend by the IDMC. Still, the firm lowered its price target on the safety update, which it calls “important to monitor going forward.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating
- Cabaletta Bio price target lowered to $3 from $6 at Wells Fargo
- Cabaletta Bio price target lowered to $13 from $26 at Stifel
- Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
- Cabaletta Bio reports Q4 EPS (65c), consensus (63c)